IBDEI2NL ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44529,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Ovary
 ;;^UTILITY(U,$J,358.3,44529,1,4,0)
 ;;=4^Z85.43
 ;;^UTILITY(U,$J,358.3,44529,2)
 ;;=^5063420
 ;;^UTILITY(U,$J,358.3,44530,0)
 ;;=Z85.46^^200^2229^96
 ;;^UTILITY(U,$J,358.3,44530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44530,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Prostate
 ;;^UTILITY(U,$J,358.3,44530,1,4,0)
 ;;=4^Z85.46
 ;;^UTILITY(U,$J,358.3,44530,2)
 ;;=^5063423
 ;;^UTILITY(U,$J,358.3,44531,0)
 ;;=Z85.47^^200^2229^100
 ;;^UTILITY(U,$J,358.3,44531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44531,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Testis
 ;;^UTILITY(U,$J,358.3,44531,1,4,0)
 ;;=4^Z85.47
 ;;^UTILITY(U,$J,358.3,44531,2)
 ;;=^5063424
 ;;^UTILITY(U,$J,358.3,44532,0)
 ;;=Z85.51^^200^2229^84
 ;;^UTILITY(U,$J,358.3,44532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44532,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Bladder
 ;;^UTILITY(U,$J,358.3,44532,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,44532,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,44533,0)
 ;;=Z85.528^^200^2229^89
 ;;^UTILITY(U,$J,358.3,44533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44533,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Kidney
 ;;^UTILITY(U,$J,358.3,44533,1,4,0)
 ;;=4^Z85.528
 ;;^UTILITY(U,$J,358.3,44533,2)
 ;;=^5063430
 ;;^UTILITY(U,$J,358.3,44534,0)
 ;;=Z85.6^^200^2229^80
 ;;^UTILITY(U,$J,358.3,44534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44534,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,44534,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,44534,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,44535,0)
 ;;=Z85.72^^200^2229^104
 ;;^UTILITY(U,$J,358.3,44535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44535,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,44535,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,44535,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,44536,0)
 ;;=Z85.79^^200^2229^94
 ;;^UTILITY(U,$J,358.3,44536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44536,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,44536,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,44536,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,44537,0)
 ;;=Z85.820^^200^2229^83
 ;;^UTILITY(U,$J,358.3,44537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44537,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,44537,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,44537,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,44538,0)
 ;;=Z85.828^^200^2229^98
 ;;^UTILITY(U,$J,358.3,44538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44538,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,44538,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,44538,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,44539,0)
 ;;=Z85.71^^200^2229^78
 ;;^UTILITY(U,$J,358.3,44539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44539,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,44539,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,44539,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,44540,0)
 ;;=Z65.8^^200^2229^138
 ;;^UTILITY(U,$J,358.3,44540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44540,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,44540,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,44540,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,44541,0)
 ;;=Z86.11^^200^2229^115
 ;;^UTILITY(U,$J,358.3,44541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44541,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,44541,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,44541,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,44542,0)
 ;;=Z86.13^^200^2229^82
